0 0 -0.000476989665223938 -0.000476989665223938 -0.00176662838971825 0.0100697818213939 0.00759650207578835 0.0104672732090804
Sign Up Today X
Thanks for submitting the form.
Stockreport

Gilead Sciences (NasdaqGS:GILD) Advances HIV Treatment With Promising Lenacapavir And Biktarvy Data [Yahoo! Finance]

Gilead Sciences, Inc. (GILD)  More Company Research Source: Yahoo! Finance
Last gilead sciences, inc. earnings: 4/30 04:01 pm Check Earnings Report
US:NASDAQ Investor Relations: investors.gilead.com
This upward trajectory coincides with positive developments in its HIV treatment portfolio, highlighted by successful data presentations at CROI 2025. The approval of lenacapavir for multi-drug resistant HIV and its promising trial results for once-yearly PrEP injections in significant publications emphasized Gilead's innovative edge. Coupled with robust earnings in Q4 2024, where revenue and net income grew from the previous year, and a positive outlook for 2025 sales excluding Veklury, investor confidence appears bolstered. Additionally, the general market saw a modest recovery with Nasdaq appreciating, although tech stocks were more positively impacted. The 2.6% dividend increase also suggests strong financial health, likely enhancing Gilead's attractiveness to investors. Overall, these events seem to have positively influenced Gilead's stock performance amid broader market volatility. Explore the potential challenges for Gilead Sciences in our thorough risk analysis report. Na [Read more]
IMPACT SNAPSHOT EVENT TIME: GILD
Last Price
Price Change
Price Change %
Volume Shares
Max Up
Max Down
Volume Ratio
%
Performance comparison Updated
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
LAST
PRICE AT
NEWS EVENT
SINCE EVENT
Multi-day stock performance from the time of the news release
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
LAST
PRICE AT
NEWS EVENT
SINCE EVENT
Multi-day stock performance from the time of the news release
LAST PRICE
VWAP
High:
MAX UP
High:
Low:
MAX DOWN
Low:
%
 POST NEWS RANGE
%
PRICE CHANGE
PRICE CHANGE PERCENTAGE
S&P 500 (SPX)
%
 VOLUME RATIO
%
VOLUME (SHARES)
TICKS
AVG SHARES PER TRADE
Don't Miss Out On The Next BIG Stock Move
EVENT DAY
Event Day Chart will not be displayed beyond 90-day period of the event
PERFORMANCE SINCE EVENT
TIME AND VELOCITY ANALYSIS
Opt-in for
GILD alerts
from News Quantified
GILD
NEWS
GILD
Earnings
GILD
Analyst Actions
GILD
SEC Filings
Stockreport

Gilead Sciences (NasdaqGS:GILD) Advances HIV Treatment With Promising Lenacapavir And Biktarvy Data [Yahoo! Finance]

Gilead Sciences, Inc.  (GILD) 
More Company Research Source: Yahoo! Finance
Last gilead sciences, inc. earnings: 4/30 04:01 pm Check Earnings Report
US:NASDAQ Investor Relations: investors.gilead.com
This upward trajectory coincides with positive developments in its HIV treatment portfolio, highlighted by successful data presentations at CROI 2025. The approval of lenacapavir for multi-drug resistant HIV and its promising trial results for once-yearly PrEP injections in significant publications emphasized Gilead's innovative edge. Coupled with robust earnings in Q4 2024, where revenue and net income grew from the previous year, and a positive outlook for 2025 sales excluding Veklury, investor confidence appears bolstered. Additionally, the general market saw a modest recovery with Nasdaq appreciating, although tech stocks were more positively impacted. The 2.6% dividend increase also suggests strong financial health, likely enhancing Gilead's attractiveness to investors. Overall, these events seem to have positively influenced Gilead's stock performance amid broader market volatility. Explore the potential challenges for Gilead Sciences in our thorough risk analysis report. Na [Read more]
IMPACT SNAPSHOT
EVENT TIME:
GILD
Last Price
Price Change
Price Change %
Volume Shares
Max Up
Max Down
Volume Ratio
%
Don't Miss Out On The Next BIG Stock Move
Performance comparison Updated
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
LAST PRICE AT
NEWS EVENT
SINCE EVENT
Multi-day stock performance from the time of the news release
LAST PRICE
VWAP
High:
MAX UP
High:
Low:
MAX DOWN
Low:
%
 POST NEWS RANGE
%
PRICE CHANGE
PRICE CHANGE PERCENTAGE
S&P 500 (SPX)
%
 VOLUME RATIO
%
VOLUME (SHARES)
TICKS
AVG SHARES PER TRADE
EVENT DAY
Event Day Chart will not be displayed beyond 90-day period of the event
PERFORMANCE SINCE EVENT
TIME AND VELOCITY ANALYSIS